Jewish Company Literally Harvesting “Young Blood” for Wealthy to Inject
Ambrosia: the Jewish startup “harvesting the blood of the young” for the wealthy elite to inject into their veins, offering vague promises of renewed youth and vigor.
IN Monterey, California, a new “medical” startup has emerged, offering transfusions of human plasma: 1.5 litres at a time, pumped in across two days per session, harvested only from the young and marketed to the very wealthy not-so-young, a disproportionate number of whom are Jews.
Ambrosia, the vampiric startup concerned, is run by a 32-year-old Jewish doctor called Jesse Karmazin, who bills $8,000 (£6,200) for each session for participation in what he has dubbed a “study”. So far, he has 600 clients, with a median age of 60. The blood is collected from local blood banks, then separated and combined – it takes multiple donors to make one package.
It’s no coincidence his scheme is based near San Francisco. The idea has become faddish in tech circles — and, may we add, in the minds of perverts: twisted in uno, twisted in omnibus. While anti-aging products usually hold more appeal with women, two-thirds of the more than 65 participants who have signed up for this so-called “trial” are men — making one wonder whether the nice Jewish doctor has been reading up on the millions made by the goat-gland and monkey-gland quacks of the last century, who falsely promised older men renewed sexual potency for some very hefty fees.
Mike Judge’s Silicon Valley sitcom recently parodied the notion, with arch-tech guru Gavin Belson relying on a “blood boy” following him around to donate pints of sticky red at inopportune moments.
Many regard the concept of injecting “young blood” to have its origins in the alleged Jewish ritual murder of White children, which some say only tapered off — but did not stop — in recent years. In the 17th century, Robert Boyle – he of Boyle’s Law – suggested “replacing the blood of the old with the blood of the young,” but he was probably just repeating medieval kabbalistic nonsense.
The consensus, according to Wikipedia, is that the practice, even apart from its sickening ghoulishness and the terrifying precedent it sets, is pseudoscience and quackery:
Young blood transfusion refers to transfusing blood specifically from a young person into an older one with the intention of creating a medicinal benefit. The scientific community currently views the practice as essentially pseudoscientific, with comparisons to snake oil.
A startup company, Ambrosia, has been selling “young blood transfusions” for $8,000 under the guise of running a clinical trial, to see if such transfusions lead to changes in the blood of recipients…. The clinical trial has no control arm and so is neither randomized nor blind. The company was started by Jesse Karmazin, a medical school graduate without a license to practice medicine…. Jonathan Kimmelman, a bioethicist from McGill University, suggests that Ambrosia is running this trial as they would be unable to get FDA approval to sell this treatment otherwise.
As of 2018 another organization, the Young Blood Institute, promotes young blood transfusion. Like Ambrosia’s, its trial had no control and charged the participants for entry, in this case $285,000 per person.
The scientific community has rolled its eyes at the “trial” element of Ambrosia. There is no control group and, with participation costing so much, no one involved is very randomised. Despite these criticisms of the science, Dr Karmazin is still reporting positive results.
Improvements in sleep are also claimed: “As people get older, they have much more difficulty sleeping,” Karmazin noted. Improve sleep and supposedly you get benefits in mood, immune system, weight management, and much else.
It begs the question, though: How could anyone sleep at night after leeching the blood out of busboys and students — and the other desperate losers in today’s vulture/vampire economy — who are reduced to selling their blood to the likes of Jesse Karmazin?
* * *
Source: based on an article in The Guardian; and National Vanguard correspondents